Redox systems are often deregulated in cancer. To investigate whether altered expression predicted response to therapy, core biopsies from 80 locally advanced breast tumours (pre-six cycles of fluorouracil epidoxorubicin cyclophosphamide/fluorouracil adriamycin cyclophosphamide chemotherapy) were stained, using standard immunohistochemistry, to examine members of the Trx system (Trx1, TrxR and TxNIP), GST-π, GST-θ, catalase and MnSOD, and results were correlated with clinicopathological criteria. Significant results were obtained between TxNIP and progression-free survival (*P*= 0.008) and overall survival (*P*= 0.05), with low expression predicting a worse prognosis. A redox protein profile was developed, using an artificial neural network approach, with four of the proteins (catalase, GST-θ, GST-π and TxNIP), that stratifies patients into good/poor prognostic groups for overall survival with an 88% sensitivity and 87% specificity.

Conventional *in vitro*studies show that, using MCF-7 cells, targeting the Trx system by pretreatment with novel inhibitors (PMX464, PMX290 or IV-2) sensitises resistant cells to conventional C/T but that sensitivity of the parental line remains unchanged. Initial results, using single agents in novel three-dimensional (3D) systems, shows differential chemosensitivity, between normal and malignant cells, that is not apparent using conventional two-dimensional (2D) systems. Parental cell lines (MCF-7, MDA-MB-231) maintain or become more sensitive when exposed in 3D to conventional chemotherapy and Trx inhibitors (doxorubicin, PMX464/PMX290, IV-2 that is IC~50~2D and 3D 0.01 μM, 0.5 μM, 25 μM - paclitaxel IC~50~3D \<0.01 μM, 2D 0.01 μM), assessed by clonogenic survival. Normal breast epithelial cells (MCF10As), however, show increased resistance to drugs (paclitaxel, doxorubicin, PMX464/PMX290, IV-2 IC~50~3D 0.1 μM, 1 μM, \>10 μM, 200 μM - IC~50~2D 0.05 μM, 0.01 μM, 0.5 μM, 25 μM, respectively). The reasons for such altered chemosensitivity in 3D matrices are a focus of current work.

Results from the immunohistochemistry and *in vitro*studies suggest the suitability of targeting redox proteins, particularly the Trx system, in breast cancer to improve the efficacy of conventional therapies.
